Clinical Trials for Prostate Cancer
536 prostate cancer trials indexed, 273 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Prostate Cancer
Prostate cancer is a disease where cells in the prostate gland grow uncontrollably. The prostate is a small gland in men that produces fluid for semen. Cancer starts when changes occur in the DNA of prostate cells, causing them to multiply faster than normal and avoid cell death. Over time, these abnormal cells can form tumors and may spread to other parts of the body. Doctors diagnose prostate cancer using a combination of tests, including prostate-specific antigen (PSA) blood tests, digital rectal exams (DRE), and biopsies. Imaging tests like MRI or CT scans can help determine the extent of the disease.
Common symptoms of prostate cancer often do not appear in early stages. When symptoms do occur, they may include difficulty urinating, frequent urination especially at night, blood in urine or semen, and pelvic discomfort. Prostate cancer mostly affects men over the age of 50, with risk increasing as men get older. It is more common in African American men and those with a family history of the disease. Other risk factors include diet, obesity, and certain genetic mutations.
Prostate cancer is medically significant because it is one of the most common cancers among men worldwide. In the United States, about 1 in 8 men will be diagnosed with prostate cancer during their lifetime. According to recent data, over 250,000 new cases are diagnosed annually in the U.S. alone. Socially, prostate cancer impacts families and healthcare systems due to its prevalence and the long-term nature of treatment and monitoring. The economic burden is substantial, with billions spent yearly on treatment and care. Early diagnosis and management remain key to improving outcomes for many men.
The Prostate Cancer Treatment Landscape
The first-line treatment for prostate cancer depends on the stage and grade of the tumor. For localized prostate cancer, options often include active surveillance, surgery (such as radical prostatectomy), or radiation therapy. Active surveillance is chosen when the cancer is slow-growing, requiring regular monitoring without immediate treatment. Surgery and radiation aim to remove or destroy cancer cells. Hormone therapy, which lowers or blocks testosterone, may also be used initially, especially if the cancer is more advanced or aggressive.
For patients whose cancer progresses or returns, second- and third-line treatments come into play. These include androgen receptor inhibitors, chemotherapy, and newer hormone therapies. Drug classes like taxanes (e.g., docetaxel) are common chemotherapy agents used after hormone therapy resistance develops. Other medications, such as abiraterone and enzalutamide, target hormone pathways differently to slow cancer growth. Immunotherapy and targeted therapies are also being explored, though they are not yet standard for all cases.
Despite these options, gaps remain in prostate cancer treatment. Some subgroups, such as those with aggressive or metastatic disease, respond poorly to current therapies. Resistance to hormone therapy is a major challenge, leading to castration-resistant prostate cancer. Side effects from treatments, including urinary incontinence, sexual dysfunction, and fatigue, can affect quality of life. Research is focused on finding treatments with fewer side effects, overcoming resistance, and improving outcomes for advanced cases.
Why Clinical Trials Matter for Prostate Cancer
Clinical trials offer patients access to new treatments that are not yet widely available. Participating in a trial can mean closer health monitoring and support from a medical team. It also allows patients to contribute to scientific knowledge that may help future patients. Currently, there are 536 prostate cancer clinical trials indexed on ClinicalTrials.gov, with 273 of these actively recruiting participants. This shows a strong ongoing effort to discover better treatments and improve care for this disease.
However, clinical trials come with risks that patients should understand. The effectiveness of new treatments is not guaranteed, and some trials include placebo groups, meaning some patients may not receive the experimental therapy. Additional clinic visits and tests can be required, which may be time-consuming or inconvenient. Side effects from experimental treatments might be unknown or more severe than standard options. It is important for patients to discuss these risks carefully with their healthcare providers before enrolling.
Prostate cancer clinical trials are sponsored by a variety of organizations, including academic institutions, pharmaceutical companies, and cooperative research groups. These sponsors design and fund studies to test new drugs, devices, or treatment strategies. ClinicalTrials.gov serves as a public registry where patients and doctors can find information about ongoing trials. This transparency helps connect patients with opportunities to participate and supports the overall progress in prostate cancer research.
What to Look for in a Prostate Cancer Clinical Trial
Clinical trials are categorized into four phases to test new treatments. Phase 1 trials focus on safety and finding the right dose. Phase 2 trials evaluate effectiveness and side effects. Phase 3 trials compare the new treatment to the current standard. Phase 4 trials happen after approval to monitor long-term effects. For prostate cancer, most trials are in Phase 2 with 142 studies. There are 111 Phase 1 trials, 47 Phase 3 trials, and 131 trials where the phase is not assigned.
When joining a prostate cancer trial, certain inclusion criteria must be met. Age limits often range from 18 to 85 years, depending on the study. Many trials require patients to have specific stages of prostate cancer, such as localized or metastatic. Prior treatments like surgery, radiation, or hormone therapy may affect eligibility. Some trials look for biomarkers, such as PSA levels or genetic markers. Disease duration and overall health status also play a role in inclusion.
Exclusion criteria help protect patient safety and ensure reliable results. Patients with severe heart, liver, or kidney problems are often excluded. Trials may exclude those taking certain medications that interfere with the study drug. Active infections or other cancers can also disqualify candidates. These rules help reduce risks and avoid complications during the trial. Understanding these criteria can help patients find suitable trials.
Practical matters are important when considering a clinical trial. The length of a prostate cancer trial can vary from a few months to several years. Visit schedules might include frequent check-ups, lab tests, and imaging. Some trials require travel to specialized centers, which could be a challenge. Patients should ask the research team four key questions: What are the possible side effects? How often will I need to visit? What happens if I decide to leave the trial early? Are there costs or travel expenses covered?
Primary Sources and Further Reading
For more detailed information about prostate cancer clinical trials, trusted sources offer reliable guidance. These websites provide updates on ongoing studies, treatment options, and patient support resources. Reviewing these materials can help patients and caregivers make informed decisions.
- National Cancer Institute: Prostate Cancer
- MedlinePlus: Prostate Cancer
- ClinicalTrials.gov: Prostate Cancer Trials
- Centers for Disease Control and Prevention: Prostate Cancer
Latest Research and Emerging Treatments for Prostate Cancer (2026)
Recent prostate cancer research is exploring new ways to tailor treatment based on individual risk and disease stage. One important study is testing less intense and more intense hormone therapies combined with radiation for patients with high-risk prostate cancer. This approach uses gene risk scores to guide treatment intensity, aiming to reduce side effects for those with lower risk while improving outcomes for higher-risk patients (NCT04513717). Hormone therapies like apalutamide and bicalutamide work by blocking male hormones that fuel prostate cancer growth. Adjusting treatment based on genetic information could make prostate cancer treatment more personalized and manageable.
New drugs for prostate cancer are also being tested to improve survival for advanced cases. For example, a combination of olaparib and abiraterone is being studied as a first-line therapy for men with metastatic castration-resistant prostate cancer who have not yet had chemotherapy (NCT05171816). Olaparib belongs to a class of drugs called PARP inhibitors, which may help block cancer cells from repairing their DNA. Abiraterone lowers hormone levels that prostate cancer cells need to grow. This combination aims to slow disease progression with potentially fewer side effects compared to older treatments.
Another promising trial is evaluating saruparib alongside new hormonal agents like darolutamide and enzalutamide for men with metastatic castration-sensitive prostate cancer (NCT06120491). Saruparib is also a PARP inhibitor, and early data suggests it might improve progression-free survival when added to standard hormone therapies. Additionally, a study is testing pasritamig, a drug that redirects T cells to attack prostate cancer cells, in patients with advanced metastatic castration-resistant prostate cancer (NCT07164443). These new treatments could offer more options for patients facing limited choices, potentially improving quality of life and extending survival. Overall, prostate cancer new treatment 2026 efforts focus on combining targeted drugs and hormone therapies to better control the disease while considering patient tolerance.
Frequently asked questions about Prostate Cancer trials
How do I find Prostate Cancer clinical trials?
The authoritative source for Prostate Cancer clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 536 prostate cancer studies are currently indexed. You can search by entering "prostate cancer" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new prostate cancer trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Prostate Cancer trials in?
Across the 536 prostate cancer trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Prostate Cancer clinical trials are currently recruiting?
As of the latest scan, 273 prostate cancer trials have a "Recruiting" status on ClinicalTrials.gov, out of 536 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting prostate cancer trial matches their tracked condition.
Stay informed about prostate cancer research
Get a weekly briefing with the trials that matter most.